Cargando…

CYP3A5*3 and SLCO1B1 c.521T>C Polymorphisms Influence the Pharmacokinetics of Atorvastatin and 2-Hydroxy Atorvastatin

There is a large variability in individual responses to atorvastatin administration. This study assessed the pharmacogenetic effects of solute carrier organic anion transporter family member 1B1 (SLCO1B1, c.388A>G and c.521T>C) and cytochrome P450 3A5 (CYP3A5, CYP3A5*3) genetic polymorphisms o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Park, Jin-Woo, Kim, Jong-Min, Lee, Hwa-Young, Noh, Jihyeon, Kim, Kyoung-Ah, Park, Ji-Young
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9323915/ https://www.ncbi.nlm.nih.gov/pubmed/35890386 http://dx.doi.org/10.3390/pharmaceutics14071491

Ejemplares similares

SLCO1B1 Phenotype and CYP3A5 Polymorphism Significantly Affect Atorvastatin Bioavailability
por: Zubiaur, Pablo, et al.
Publicado: (2021)

The enhanced atorvastatin hepatotoxicity in diabetic rats was partly attributed to the upregulated hepatic Cyp3a and SLCO1B1
por: Shu, Nan, et al.
Publicado: (2016)

SLCO1B1 c.388A>G Polymorphism Is Associated with HDL-C Levels in Response to Atorvastatin in Chilean Individuals
por: Prado, Yalena, et al.
Publicado: (2015)

Effects of Soy Isoflavones and Green Tea Extract on Simvastatin Pharmacokinetics and Influence of the SLCO1B1 521T > C Polymorphism
por: Zeng, Weiwei, et al.
Publicado: (2022)

Pharmacogenetics of OATP Transporters Reveals That SLCO1B1 c.388A>G Variant Is Determinant of Increased Atorvastatin Response
por: Rodrigues, Alice C., et al.
Publicado: (2011)

Predictive Value of SLCO1B1 c.521T>C Polymorphism on Observed Changes in the Treatment of 1136 Statin-Users
por: Jansen, Marleen E., et al.
Publicado: (2023)

Meta-Analysis of the SLCO1B1 c.521T>C Variant Reveals Slight Influence on the Lipid-Lowering Efficacy of Statins
por: Dou, Ye, et al.
Publicado: (2015)

SLCO1B1*5 Allele Is Associated With Atorvastatin Discontinuation and Adverse Muscle Symptoms in the Context of Routine Care
por: Voora, Deepak, et al.
Publicado: (2022)

Pharmacokinetic drug interaction between atorvastatin and ezetimibe in healthy Korean volunteers
por: Park, Jungsin, et al.
Publicado: (2017)

Population pharmacokinetic of paracetamol and atorvastatin with co‐administration of semaglutide
por: Langeskov, Emilie K., et al.
Publicado: (2022)

Pharmacokinetics and Genetic Factors of Atorvastatin in Healthy Korean Subjects
por: Kim, Serim, et al.
Publicado: (2022)

Pharmacokinetic Interaction between Atorvastatin and Omega-3 Fatty Acid in Healthy Volunteers
por: Kim, Jae Hoon, et al.
Publicado: (2022)

CYP3A5 genotyping for assessing the efficacy of treatment with simvastatin and atorvastatin
por: Kolovou, Genovefa, et al.
Publicado: (2015)

Pharmacokinetics of fixed-dose combination of atorvastatin and metformin compared with individual tablets
por: Ghim, Jong-Lyul, et al.
Publicado: (2019)

Influence of SLCO1B1 and CYP2C8 gene polymorphisms on rosiglitazone pharmacokinetics in healthy volunteers
por: Aquilante, Christina L, et al.
Publicado: (2008)

Effect of Upadacitinib on the Pharmacokinetics of Rosuvastatin or Atorvastatin in Healthy Subjects
por: Mohamed, Mohamed‐Eslam F., et al.
Publicado: (2021)

Influence of FMO3 and CYP3A4 Polymorphisms on the Pharmacokinetics of Teneligliptin in Humans
por: Park, Jin-Woo, et al.
Publicado: (2021)

Effects of SLCO1B1 and SLCO1B3 Genetic Polymorphisms on Valsartan Pharmacokinetics in Healthy Korean Volunteers
por: Song, Gonjin, et al.
Publicado: (2021)

Pharmacokinetic interaction of garlic and atorvastatin in dyslipidemic rats
por: Reddy, G. Dilip, et al.
Publicado: (2012)

Pharmacokinetic interactions between glimepiride and rosuvastatin in healthy Korean subjects: does the SLCO1B1 or CYP2C9 genetic polymorphism affect these drug interactions?
por: Kim, Choon Ok, et al.
Publicado: (2017)

Genetic Polymorphisms in SLCO2B1 and ABCC1 Conjointly Modulate Atorvastatin Intracellular Accumulation in HEK293 Recombinant Cell Lines
por: Hoste, Emilia, et al.
Publicado: (2023)

Combined Beneficial Effect of Genistein and Atorvastatin on Adipogenesis in 3T3-L1 Adipocytes
por: Lee, Dahae, et al.
Publicado: (2021)

Atorvastatin Inhibits Endothelial PAI-1-Mediated Monocyte Migration and Alleviates Radiation-Induced Enteropathy
por: Kwak, Seo Young, et al.
Publicado: (2021)

Co-Administration of Vonoprazan, Not Tegoprazan, Affects the Pharmacokinetics of Atorvastatin in Healthy Male Subjects
por: Hwang, Sejung, et al.
Publicado: (2021)

Association Between SLCO1B1 Gene T521C Polymorphism and Statin-Related Myopathy Risk: A Meta-Analysis of Case–Control Studies
por: Hou, Qingtao, et al.
Publicado: (2015)

Pharmacokinetic interaction between fimasartan and atorvastatin in healthy male volunteers
por: Choi, Yewon, et al.
Publicado: (2018)

Pharmacokinetic Interaction between Sorafenib and Atorvastatin, and Sorafenib and Metformin in Rats
por: Karbownik, Agnieszka, et al.
Publicado: (2020)

Pharmacokinetic Interaction of Green Rooibos Extract With Atorvastatin and Metformin in Rats
por: Patel, Oelfah, et al.
Publicado: (2019)

Influence of Drug–Drug Interactions on the Pharmacokinetics of Atorvastatin and Its Major Active Metabolite ortho-OH-Atorvastatin in Aging People Living with HIV
por: Courlet, Perrine, et al.
Publicado: (2020)

Frequency distribution of polymorphisms of CYP2C19, CYP2C9, VKORC1 and SLCO1B1 genes in the Yakut population
por: Vasilyev, Filipp Filippovich, et al.
Publicado: (2016)

Effects of Simvastatin on Pharmacokinetics and Anticoagulant Effects of Dabigatran in Healthy Subjects
por: Chung, Hyewon, et al.
Publicado: (2023)

Atorvastatin-induced pancreatitis
por: Prajapati, Samir, et al.
Publicado: (2010)

Atorvastatin (Lipitor) by MCR
por: Zarganes-Tzitzikas, Tryfon, et al.
Publicado: (2019)

Association between SLCO1B1 −521T>C and −388A>G polymorphisms and risk of statin-induced adverse drug reactions: A meta-analysis
por: Jiang, Jiajia, et al.
Publicado: (2016)

Impact of polymorphisms in CYP and UGT enzymes and ABC and SLCO1B1 transporters on the pharmacokinetics and safety of desvenlafaxine
por: Calleja, Sofía, et al.
Publicado: (2023)

The independent contribution of miRNAs to the missing heritability in CYP3A4/5 functionality and the metabolism of atorvastatin
por: Liu, Ju-E, et al.
Publicado: (2016)

Effect of Semaglutide on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin and Digoxin in Healthy Subjects
por: Hausner, Helene, et al.
Publicado: (2017)

A pharmacokinetics‐based approach to the monitoring of patient adherence to atorvastatin therapy
por: Karvaly, Gellért Balázs, et al.
Publicado: (2021)

[(18)F]Atorvastatin Pharmacokinetics and Biodistribution in Healthy Female and Male Rats
por: Clemente, Gonçalo S., et al.
Publicado: (2021)

Pharmacokinetic and pharmacodynamic drug-drug interaction of Nomilin with atorvastatin in hyperlipidemic mice
por: Ding, Yan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_a3491csh70e8ppo3fmdjfuu1n9